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Abstract
Backgrounds: Cisplatin-based chemotherapy, in combination with fluoropyrimidines or taxanes, have
demonstrated efficacy against advanced gastric cancer (AGC). This retrospective study was performed with the data
obtained from our cancer chemotherapy registry and eight another cancer centers.
Methods: In 2008, a total of 283 AGC patients were treated with cisplatin-based doublet chemotherapy in the first-
line setting: capecitabine plus cisplatin (XP, n = 77), S-1 plus cisplatin (SP, n = 97), taxanes (docetaxel, paclitaxel)
plus cisplatin (TP, n = 72), and 5-fluorouracil plus platinum (FP, n = 37). The primary endpoint of this study was
overall survival (OS) and the secondary endpoints were safety, response rate and progression-free survival (PFS).
Results: The median age was 54 years with a range of 28-78 years and median delivered number of
chemotherapy cycles were XP: 4, SP: 5, TP: 5 and FP: 5, respectively. Objective tumor responses (38%; 95% CI, 32-
43%) were 40% for XP, 42% for SP, 36% for DP, and 24% for FP. The estimated median PFS was 4.5 months (95%
CI, 3.6-5.4 months) and the median OS was 12.3 months (95% CI, 10.8-13.7 months). No statistically significant
difference was found between each regimen used as first-line chemotherapy. At multivariate analysis, independent
prognostic parameters for OS were prior gastrectomy, peritoneal dissemination, performance status and
hemoglobin level
Conclusion: All of the cisplatin-based doublet chemotherapy regimens appear to be active as first-line
chemotherapy for AGC. With better patient selection according to clinical parameters and molecular markers,
clinical outcomes of AGC patients in first-line setting can be improved.
Background
Gastric cancer is the most frequently occurring malig-
nancy in Korea, and is one of the main causes of cancer
death [1]. For patients with recurrent, metastatic, or
advanced gastric cancer (AGC), chemotherapy can
improve survival, and possibly, provide significant pallia-
tion of symptoms [2,3]. Several randomized trials have
demonstrated that 5-fluorouracil (5-FU)-based che-
motherapy is superior to best supportive care in terms
of survival and preservation of quality of life (QOL)
[2,3]. While the treatment options for AGC have
expanded in recent years to include newer agents such
as taxanes (paclitaxel and docetaxel), irinotecan and
oxaliplatin, the prognosis of AGC patients remains poor.
Multi-drug combination chemotherapy regimens have
generally provided significantly higher response rates,
but no better overall survival [4]. Despite the lack of evi-
dence for benefit associated with cisplatin-based combi-
nation chemotherapy, it is a common practice to offer
cisplatin-based doublet or triplet chemotherapy for AGC
patients in the first-line setting, because 5-FU mono-
therapy has only limited activity. Recently, oral fluoro-
pyrimidines, including capecitabine and S-1, are
replacing infusional 5-FU. Both capecitabine and S-1 are
considered to be more tolerable than 5-FU, and has
been shown to exhibit antitumor activity against AGC
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cisplatin-based doublet or triplet, has also produced sig-
nificant benefit for AGC patients [8-10]. Although it is
currently unclear whether combination of 3 active drugs
is superior to doublet combination, our recent rando-
mized study suggested that cisplatin-based doublet and
triplet chemotherapy showed similar outcomes [11].
A decision of chemotherapy regimens for an indivi-
dual patient may be a common clinical situation. Factors
considered include the extent of disease, the potential
toxicity, especially for those with impaired swallowing or
with low performance status, as well as the activity of
chemotherapy. Because well-designed, randomized, con-
trolled clinical trials are sparse in AGC, an exploratory,
or retrospective analysis seems to be an important
source of data to allow the definition of optimal treat-
ment, enhance patient counseling, and generate hypoth-
eses for future studies. We therefore decided to evaluate
cisplatin-based combination regimens as first-line che-
motherapy for AGC. The present evaluation was also
done with the intent to plan and develop improved ther-
apeutic strategies for chemotherapy-naïve AGC patients.
Methods
This is a multicenter, retrospective study. Between January
and December 2008, 283 patients were treated with first-
line cisplatin-based doublet combination regimens at 9
tertiary centers in Korea. Thec r i t e r i af o rc a s ei n c l u s i o n
were as follows: (1) histologically confirmed diagnosis of
gastric adenocarcinoma, (2) no prior chemotherapy or
radiotherapy except for adjuvant treatments, (3) presence
of metastatic disease, (4) availability of clinical data at the
beginning of therapy and follow-up. All patients had been
treated with taxane/cisplatin or fluoropyrimidine/cisplatin
doublet combination regimens as their first-line therapy
for advanced disease. We excluded patients who were
enrolled in clinical trials to ensure the choice of che-
motherapy regimen was at the discretion of the treating
physician. We collected follow-up patient data from the
cancer registry. All the data was prospectively recorded
and only the survival data was updated at the time of ana-
lyses. Written informed consent was given by all patients
prior to receiving chemotherapy, according to institutional
guidelines. Approval of the study was obtained from the
institutional review board or ethics committee.
All patients received cisplatin-based first-line che-
motherapy for AGC. Cisplatin was, in all cases, given at a
dose of 60-100 mg/m
2 infusion on day 1 in combination
with capecitabine (1000 mg/m
2 bid po on days 1-14, XP; n
= 77), S-1 (40 mg/m
2 bid po on days 1-21, SP; n = 97),
docetaxel (75 mg/m
2 iv on day 1, DP; n = 72), or 5-FU
(800-1000 mg/m
2iv on days 1-5 as a protracted continu-
ous infusion, FP; n = 37). Chemotherapy was repeated
every 3 weeks (XP, DP and FP) or every 5 weeks (SP)
according to the regimen. The treating physician deter-
mined chemotherapy regimen, as well as the initial dose of
cisplatin, for each patient. Treatment was continued until
disease progression or lack of clinical benefit, withdrawal
of consent, justifiable withdrawal at the investigator’s dis-
cretion, or toxicity. Toxicities were graded according the
National Cancer Institute (NCI) criteria (CTCAE v3). The
dosage of the subsequent cycles was adjusted according to
the toxic effects that developed during the preceding cycle.
All patients received standard supportive regimen consist-
ing of hydration and antiemetics. The prophylactic use of
hematopoietic growth factors was not allowed during
treatment, except for patients with febrile neutropenia or
grade 4 myelosuppression at the treating physician’sd i s -
cretion. After this combination chemotherapy had failed,
second-line chemotherapy was recommended to all the
patients if their performance status was preserved.
According to the guidelines and department policies, all
tumor measurements were assessed after every 2 courses
of chemotherapy, by using spiral abdominopelvic com-
puted tomography (CT) scan and other tests that were
used initially to stage the tumor. Tumor response was
evaluated according to the Response Evaluation Criteria
for Solid Tumors (RECIST) [12]. As a general principle for
determining clinical response, a confirmatory CT scan was
recommended at least 4 weeks apart.
The primary endpoint of this study was overall survi-
val (OS). The starting point of OS and progression-free
survival (PFS) was the first day of chemotherapy. The
date of disease progression or death from causes other
than AGC was used in calculating PFS. Time to death,
whatever the cause, was used to calculate OS. PFS and
OS were estimated according to the Kaplan-Meier
method and the statistical significance of survival curves
between groups was tested with a log-rank test. To
examine the impact of clinical and treatment variables
on the outcomes of chemotherapy, multivariate Cox
regression models were used. Covariates included were
age (below vs. ≥ median), gender, previous gastrectomy,
an Eastern Cooperative Oncology Group (ECOG) per-
formance status (0-1 vs. ≥2), weight loss (>5%) before
treatment, number of involved sites (one vs. ≥2), metas-
tases (liver, bone, and bone marrow), presence of ascites,
baseline chemistry profiles (serum albumin, alkaline
phosphatase, and bilirubin), and chemotherapy regi-
mens. Laboratory parameters were initially recorded as
continuous variables and later dichotomized according
to the median value of each variable (below vs. ≥ med-
ian). All P values were two-sided, with P < 0.05 indicat-
ing statistical significance.
Results
Patient characteristics included in this analysis are
shown in Table 1. The median age was 54 years with a
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were male, and 12% had an ECOG performance status
of 2. Seventy-three patients had received gastrectomy
for curative intent, and 63 patients received adjuvant
chemotherapy or chemoradiotherapy. About one-thirds
of patients had two or more metastatic disease sites,
mostly involving peritoneum and abdominal lymph
node. We noted that more DP patients had received
adjuvant therapy involving 5-FU, less XP patients had
an ECOG performance status of 2, and most of FP
patients had peritoneal dissemination at the time of pre-
sentation. At the time of data collection, 244 (86%)
patients progressed and 177 (63%) were known to have
died.
A total of 1299 chemotherapy courses were adminis-
tered. Median numbers of chemotherapy courses for
XP, SP, DP and FP were 4, 5, 5 and 5, respectively. The
most common reason for treatment discontinuation was
disease progression. Overall, cisplatin-based combination
chemotherapy was generally well tolerated. We found no
relevant difference in the occurrence of grade 3 or 4
toxicities between regimens (Table 2). Two possible
treatment-related deaths were identified. One death
occurred in the midst of treatment with XP, with no
clinical evidence of progression having been demon-
strated. Two other deaths occurred in patients while
receiving FP, which were attributed to neutropenic
sepsis.
Of a total of 283 patients, 22 could not be evaluated
for responses because of the absence of any measurable
lesions or early discontinuation of therapy. Objective
responses to cisplatin-based chemotherapy were noted
in 107 patients (response rate, 38%; 95% confidence
interval [CI], 32-43%), including two complete responses
seen in XP patients; 40% for XP, 42% for SP, 36% for
DP, and 24% for FP. Patients who had a poor perfor-
mance status (≥2 in ECOG scale) were significantly less
likely to respond to first-line chemotherapy (24% vs.
40%; p < 0.001) compared to those with an ECOG per-
formance status of 0 or 1. Other factor associated with
lack of optimal response was the presence of peritoneal
dissemination (31% vs. 45%; p = 0.047). Response rate
was not significantly influenced by age, gender, weight
loss, baseline laboratory parameters, metastasis, or che-
motherapy regimen.
The estimated median PFS was 4.5 months (95% CI,
3.6-5.4 months) and the median OS was 12.3 months
(95% CI, 10.8-13.7 months). PFS was shorter in patients
receiving DP or FP (3.9 months and 3.9 months, respec-
tively) than those receiving XP (5.4 months) or SP (5.7
months). In particular, XP patients had a longer PFS
that FP patients (hazard ratio, 0.79; 95% CI, 0.52-1.21;
p = 0.29). However, no statistically significant difference
in the OS was found between each regimen used as
first-line chemotherapy (Figure 1). In the univariate
model, the estimated OS was significantly longer for
patients with a history of prior gastrectomy, good per-
formance status, normal baseline hemoglobin, single
metastatic site, and the absence of peritoneal dissemina-
tion (Table 3). Multivariate regression model included
the 5 parameters that were found to have prognostic
significance in univariate analysis. These parameters
were available for all 283 patients. At multivariate analy-
sis, independent prognostic parameters for OS were
prior gastrectomy, peritoneal dissemination, perfor-
mance status and hemoglobin level (Table 4). We also
tested whether the OS was modified by interaction
between the effect of other significant clinical para-
meters and chemotherapy regimens given; the first-level
interaction term between these variables was entered
into separate multivariate model. However, we found no
interaction between any first-line chemotherapy regimen
with each clinical parameters.
After first-line failure, second-line chemotherapy was
administered for more than half of patients (n = 162).
Specifically, 34 (44%) XP patients received second-line
chemotherapy, and 55 (57%) SP patients, 49 (68%) DP
patients and 24 (65%) FP patients were treated with
Table 1 Patient characteristics
XP (n =
77)
SP (n =
97)
DP (n =
72)
FP (n =
37)
Age, years
Median 59 53 51 60
Range 35-77 33-75 28-78 30-75
Gender
Male 55 63 41 20
Female 22 34 31 17
ECOG performance
status
01 7 1 5 1 0 4
15 6 7 0 5 1 2 7
2 4 12 11 6
Prior therapy
Curative resection 11 22 33 7
Palliative
gastrectomy
24 27 16 16
Adjuvant therapy 6 18 31 8
Involved sites(s)
Abdominal lymph
nodes
55 64 39 12
Liver 23 25 16 8
Lung 3 7 3 3
Peritoneum 41 45 39 28
Bone 3 8 9 1
Ovary 4 7 3 1
XP; capecitabine + cisplatin; SP, S-1 + cisplatin; DP, docetaxel + cisplatin; FP,
5-fluorouracil + cisplatin; ECOG, Eastern Cooperative Oncology Group.
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receive second-line chemotherapy (13.9 vs. 10.1 months,
p = 0.024) than in those without further treatment.
Discussion
Despite recent advances in the treatment of AGC [13],
AGC patients treated with first-line chemotherapy have
median OS rarely exceeding 12 months. In the current
multicenter, retrospective analysis, outcomes for AGC
a r ec o m p a r a b l et ot h o s ei nt h ep u b l i s h e dt r i a l so fc o m -
bination chemotherapy. Although this study is retro-
spective in nature, the results provide a piece of
evidence that patients with AGC may derive an indispu-
table benefit from cisplatin-based doublet chemotherapy.
AGC is an incurable condition where the aim of treat-
ment is to improve survival and to palliate symptoms.
Disease may respond to several types of chemotherapy
initially, and these treatments have been shown to pro-
vide palliation as indicated by improvement in duration
and/or quality of survival [2,3]. The best choice of che-
motherapy regimen for patients with AGC is still a mat-
ter of controversy and requires further investigation [4].
Currently, fluoropyrimidine and cisplatin combination
chemotherapy is accepted as a standard regimen by
many oncologists. It is presently unclear whether the tri-
plet combination is superior to cisplatin-based doublets
for patients with AGC. A meta-analysis showed a differ-
ence in OS of approximately 2 months in favor of the
anthracycline-containing triplets versus doublets [13].
Table 2 Chemotherapy compliance and toxicity
XP (n =
77)
SP (n =
97)
DP (n =
72)
FP (n =
37)
Chemotherapy courses
Median 4 5 5 4
Range 1-9 1-15 1-10 1-14
Reasons for
discontinuation
Progressive disease 28 41 49 21
Toxicity 6 6 4 3
Withdrawal 3 16 3 4
Physician
recommendation
34 29 14 9
Unknown 6 5 2 0
Overall grade 3 or 4
toxicity
68 73 67 30
Treatment-related deaths 1 0 0 2
Figure 1 Overall survival according to chemotherapy regimens
Table 3 Univariate analysis according to baseline clinical
parameters
OS, mo* 95% CI P
Previous gastrectomy No 10.9 8.8-13.1 .001
Yes 13.9 12.5-15.4
Gender Male 13.3 11.8-14.7 .315
Female 11.8 9.5-14.2
Age <median 11.8 10.3 - 13.4 .279
≥median 13.4 11.3 - 15.4
Performance status 0 or 1 13.3 11.9 - 14.6 <.001
≥2 5.9 1.0 - 10.8
Hemoglobin <10 g/dL 7.9 6.0 - 9.8 <.001
≥10 g/dL 13.4 10.3 - 16.4
No. of involved site(s) 1 12.8 11.4 - 14.3 .048
≥2 8.5 6.7 - 10.3
Liver metastasis No 12.2 10.4 - 14.1 .654
Yes 12.2 9.5 - 14.8
Bone metastasis No 12.6 10.7 - 14.2 .144
Yes 8.2 6.5 - 9.5
Peritoneal dissemination No 13.9 12.4 - 15.4 .008
Yes 10.6 8.4 - 12.7
Weight loss No 12.6 10.8 - 14.4 .580
Yes 12.0 9.6 - 14.3
Chemotherapy XP 11.2 6.7 - 15.7 .673
SP 13.3 11.7 - 14.8
DP 12.0 8.6 - 15.4
FP 11.3 7.1 - 15.5
* OS, median overall survival; 95% CI, 95% confidence interval.
Table 4 Multivariate analysis according to baseline
clinical parameters
P Hazard ratio 95% CI
No prior gastrectomy 0.002 0.618 0.456-0.836
Two or more metastatic sites 0.347 0.831 0.566-1.222
Peritoneal dissemination 0.013 0.663 0.479-0.916
Low hemoglobin 0.002 0.740 0.610-0.896
Poor performance status <0.001 0.375 0.245-0.574
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study comparing epirubicin, cisplatin plus capecitabine
combination with cisplatin plus capecitabine doublet
showed similar efficacy outcomes [11]. Among other 3-
drug combination regimens, docetaxel-containing triplet
chemotherapy (docetaxel, cisplatin and 5-FU) showed
superior time-to-progression (5.6 months vs. 3.7
months) to doublet (cisplatin and 5-FU) [10]. However,
the observed OS benefit of triplet was less than one
month (9.2 months vs. 8.6 months), and there was sub-
stantial grade 3 or 4 toxicity.
In our analysis, there appears to be no advantage of
one cisplatin-based doublet over the others. While there
was no relevant difference is OS between treatment
groups, it is worth considering the possible role that
second-line therapy could have had on survival. More
than half of patients received second-line chemotherapy.
Furthermore, our observation that PFS was shorter with
DP or FP than XP or SP is likely related to negative
prognostic factors influencing the choice of intravenous
chemotherapeutic agents instead of oral ones. AGC
patients who already had peritoneal dissemination, with
or without ascites, could not tolerate oral agents. Simi-
larly, we cannot rule out a possibility that the choice of
a chemotherapeutic agent depends on previous ones.
Although we could not assess time to recurrence after
the completion of adjuvant therapy, some AGC patients
have received adjuvant chemotherapy with 5-FU, so it
seems more prudent to avoid fluoropyrimidines in the
first-line regimen for reasons of efficacy. Patients with
rapidly progressing disease are an unfavorable setting of
patients unlikely to benefit from first-line chemotherapy.
For the present, the decision to use specific drug(s) in
patients with AGC should be determined by their rela-
tive merits on a case-by-case basis.
It is also necessary to better define the sub-population
of patients who truly benefit from combination che-
motherapy because there is potential for toxicity from
the treatment. Therefore, the identification of factors
allowing the selection of patients who are likely to bene-
fit from chemotherapy is an important challenge. In a
pooled analysis of 3 randomized trials, Chau et al. [14]
investigated the prognostic significance of the baseline
factors in 1080 chemotherapy-naïve patients with eso-
phagogastric cancer. They found that poor performance
status, metastases to liver and peritoneum, and alkaline
phosphatase significantly predicted poor survival. Our
previous retrospective study in 1455 AGC patients have
revealed that poor prognostic factors were no previous
gastrectomy, low albumin, high alkaline phosphatase,
bone metastasis, the presence of ascites, and a poor per-
formance status [15]. In the current study, hemoglobin
level, along with prior gastrectomy, peritoneal dissemi-
nation of disease and performance status, emerged as
the significant survival predictor. When interpreting the
results, it is of note that this analysis represents only a
small sample of patients, and we cannot completely
exclude the possibility that lower levels of performance
status may be reflective of other occult predictors for a
poor prognosis.
Although it is conceived that the rationale for offering
palliative gastrectomy to patients with unresectable or
metastatic gastric cancer is to avoid tumor bleeding,
perforation, obstruction, or to improve the outcome by
reducing tumor burden, the role of palliative gastrect-
omy in AGC patients with metastatic disease needs clar-
ification[15]. A randomized trial (reductive gastrectomy
for advanced tumor in two Asian countries, REGATTA,
KGCA01/JCOG0705) is underway. Besides clinical para-
meters, appropriate patient selection based on molecular
markers is one of the most extensively studied areas in
clinical research. While it is still at an early stage and it
would take years before we can see clinical application,
extensive work is ongoing to identify possible molecular
markers, including epidermal growth factor receptor
(EGFR) or vascular endothelial growth factor (VEGF)
expression [16,17], Her2/neu amplification [18], and
excision repair cross-complementing gene 1 (ERCC1)
[19], that could be linked to sensitivity or resistance to
specific agents, as well as specific genotype variations
harbored in different ethnicities. The predictive value of
KRAS mutation in metastatic colorectal cancer patients
treated with anti-EGFR monoclonal antibodies, cetuxi-
mab or panitumumab, has recently been suggested [20].
While gastric cancer is sharing many phenotypic and
molecular genetic changes with colorectal cancer, recent
molecular studies in gastric cancer have mostly found a
lower incidence of KRAS mutation than in colorectal
cancer [21,22].
Although cisplatin is often used in combination with
other agents, it is well known that cisplatin is associated
with significant toxicity and usually requires a high level
of clinical monitoring and supportive care including
intensive intravenous hydration. Oxaliplatin-based regi-
mens have been actively investigated to improve the effi-
cacy and tolerability of combination chemotherapy for
AGC patients[5,23]. Oxaliplatin has significant activity
against some cisplatin-resistant tumors and a favorable
safety profile over cisplatin[24].
The comparison of the regimens that were the focus
of this analysis suggests that cisplatin-based combination
chemotherapy may represent a therapeutic ceiling as far
as cytotoxic agents are concerned. As seen in a recent
phase III study [25], there is clearly interest in exploring
molecular markers, and it may be that further advances
in the treatment of AGC will only be achieved with
development of novel targeted agents. Also, with better
patient selection, clinical outcomes of AGC patients in
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the knowledge of disease may further guide us to
develop individualized treatment for AGC patients.
Acknowledgements
This study was supported in part by a grant of the Korea Health 21 R&D
Project, Ministry of Health & Welfare, Republic of Korea (0412-CR01-0704-
0001).
Author details
1Division of Hematology-Oncology, Department of Medicine, Sungkyunkwan
University School of Medicine, Samsung Medical Center, Seoul, Korea.
2Division of Hematology-Oncology, Department of Medicine, Dankook
University Hospital, Cheonan, South Korea.
3Department of Internal Medicine,
Post-Graduate Medical School, Gyeongsang National University, Korea.
4Department of internal medicine, Dong-A University College of Medicine,
Busan, Korea.
5Department of Internal Medicine, Chung-Ang University
College of Medicine, Seoul, Republic of Korea.
6Department of Internal
Medicine, Jeju National University School of Medicine, Jeju, Korea.
7Division
of Oncology-Hematology Department of Internal Medicine Soonchunhyang
University Hospital, Seoul, Korea.
8Department of Internal Medicine, Kangwon
National University Hospital, Kangwon National University School of
Medicine, Chuncheon, Korea.
9Division of Hematology and Oncology,
Department of Internal Medicine, Hallym University Medical Center, Hallym
University College of Medicine, Seoul, Korea.
Authors’ contributions
DHL and SHP designed the study. WKK provided advice on the study
design. DHL, KWP, JHK, SYO, IGH, JMK, SCL, HYL, HSK and HYL followed the
patients and collected the data. DHL, WKK and SHP drafted the manuscript.
All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 3 March 2010 Accepted: 26 October 2010
Published: 26 October 2010
References
1. Won YJ, Sung J, Jung KW, Kong HJ, Park S, Shin HR, Park EC, Ahn YO,
Hwang IK, Lee DH, et al: Nationwide Cancer Incidence in Korea, 2003-
2005. Cancer Res Treat 2009, 41(3):122-131.
2. Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M: Randomised comparison of
fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive
care with supportive care alone in patients with non-resectable gastric
cancer. Br J Cancer 1995, 71(3):587-591.
3. Glimelius B, Ekstrom K, Hoffman K, Graf W, Sjoden PO, Haglund U,
Svensson C, Enander LK, Linne T, Sellstrom H, et al: Randomized
comparison between chemotherapy plus best supportive care with best
supportive care in advanced gastric cancer. Ann Oncol 1997, 8(2):163-168.
4. Ohtsu A, Yoshida S, Saijo N: Disparities in gastric cancer chemotherapy
between the East and West. J Clin Oncol 2006, 24(14):2188-2196.
5. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F,
Middleton G, Daniel F, Oates J, Norman AR: Capecitabine and oxaliplatin
for advanced esophagogastric cancer. N Engl J Med 2008, 358(1):36-46.
6. Kang YK, Kang WK, Shin DB, Chen J, Xiong J, Wang J, Lichinitser M, Guan Z,
Khasanov R, Zheng L, et al: Capecitabine/cisplatin versus 5-fluorouracil/
cisplatin as first-line therapy in patients with advanced gastric cancer: a
randomised phase III noninferiority trial. Ann Oncol 2009, 20(4):666-673.
7. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, Miyashita K,
Nishizaki T, Kobayashi O, Takiyama W, et al: S-1 plus cisplatin versus S-1
alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a
phase III trial. Lancet Oncol 2008, 9(3):215-221.
8. Park SH, Kang WK, Lee HR, Park J, Lee KE, Lee SH, Park JO, Kim K, Kim WS,
Chung CW, et al: Docetaxel plus cisplatin as second-line therapy in
metastatic or recurrent advanced gastric cancer progressing on 5-
fluorouracil-based regimen. Am J Clin Oncol 2004, 27(5):477-480.
9. Park KW, Ahn JS, Park YS, Lee J, Kang JH, Park JO, Lim HY, Im YH, Kang WK,
Park K, et al: Phase II study of docetaxel and cisplatin combination
chemotherapy in metastatic gastric cancer. Cancer Chemother Pharmacol
2007, 59(1):17-21.
10. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C,
Rodrigues A, Fodor M, Chao Y, Voznyi E, et al: Phase III study of docetaxel
and cisplatin plus fluorouracil compared with cisplatin and fluorouracil
as first-line therapy for advanced gastric cancer: a report of the V325
Study Group. J Clin Oncol 2006, 24(31):4991-4997.
11. Yun J, Lee J, Park SH, Park JO, Park YS, Lim HY, Kang WK: A randomised
phase II study of combination chemotherapy with epirubicin, cisplatin
and capecitabine (ECX) or cisplatin and capecitabine (CX) in advanced
gastric cancer. Eur J Cancer 2010, 46(5):885-891.
12. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L,
Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, et al: New
guidelines to evaluate the response to treatment in solid tumors.
European Organization for Research and Treatment of Cancer, National
Cancer Institute of the United States, National Cancer Institute of
Canada. J Natl Cancer Inst 2000, 92(3):205-216.
13. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE:
Chemotherapy in advanced gastric cancer: a systematic review and
meta-analysis based on aggregate data. J Clin Oncol 2006,
24(18):2903-2909.
14. Chau I, Norman AR, Cunningham D, Waters JS, Oates J, Ross PJ:
Multivariate prognostic factor analysis in locally advanced and
metastatic esophago-gastric cancer–pooled analysis from three
multicenter, randomized, controlled trials using individual patient data. J
Clin Oncol 2004, 22(12):2395-2403.
15. Lee J, Lim T, Uhm J, Park K, Park S, Lee S, Park J, Park Y, Lim H, Sohn T,
et al: Prognostic model to predict survival following first-line
chemotherapy in patients with metastatic gastric adenocarcinoma. Ann
Oncol 2007, 18(5):886-891.
16. Galizia G, Lieto E, Orditura M, Castellano P, Mura AL, Imperatore V, Pinto M,
Zamboli A, De Vita F, Ferraraccio F: Epidermal growth factor receptor
(EGFR) expression is associated with a worse prognosis in gastric cancer
patients undergoing curative surgery. World J Surg 2007, 31(7):1458-1468.
17. Lieto E, Ferraraccio F, Orditura M, Castellano P, Mura AL, Pinto M,
Zamboli A, De Vita F, Galizia G: Expression of vascular endothelial growth
factor (VEGF) and epidermal growth factor receptor (EGFR) is an
independent prognostic indicator of worse outcome in gastric cancer
patients. Ann Surg Oncol 2008, 15(1):69-79.
18. Park DI, Yun JW, Park JH, Oh SJ, Kim HJ, Cho YK, Sohn CI, Jeon WK, Kim BI,
Yoo CH, et al: HER-2/neu amplification is an independent prognostic
factor in gastric cancer. Dig Dis Sci 2006, 51(8):1371-1379.
19. Matsubara J, Nishina T, Yamada Y, Moriwaki T, Shimoda T, Kajiwara T,
Nakajima TE, Kato K, Hamaguchi T, Shimada Y, et al: Impacts of excision
repair cross-complementing gene 1 (ERCC1), dihydropyrimidine
dehydrogenase, and epidermal growth factor receptor on the outcomes
of patients with advanced gastric cancer. Br J Cancer 2008, 98(4):
832-839.
20. Lievre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E, Ychou M,
Bouche O, Landi B, Louvet C, et al: KRAS mutations as an independent
prognostic factor in patients with advanced colorectal cancer treated
with cetuximab. J Clin Oncol 2008, 26(3):374-379.
21. Lee KH, Lee JS, Suh C, Kim SW, Kim SB, Lee JH, Lee MS, Park MY, Sun HS,
Kim SH: Clinicopathologic significance of the K-ras gene codon 12 point
mutation in stomach cancer. An analysis of 140 cases. Cancer 1995,
75(12):2794-2801.
22. Hongyo T, Buzard GS, Palli D, Weghorst CM, Amorosi A, Galli M,
Caporaso NE, Fraumeni JF Jr, Rice JM: Mutations of the K-ras and p53
genes in gastric adenocarcinomas from a high-incidence region around
Florence, Italy. Cancer Res 1995, 55(12):2665-2672.
23. Al-Batran SE, Hartmann JT, Probst S, Schmalenberg H, Hollerbach S,
Hofheinz R, Rethwisch V, Seipelt G, Homann N, Wilhelm G, et al: Phase III
trial in metastatic gastroesophageal adenocarcinoma with fluorouracil,
leucovorin plus either oxaliplatin or cisplatin: a study of the
Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 2008,
26(9):1435-1442.
24. Cvitkovic E: Ongoing and unsaid on oxaliplatin: the hope. Br J Cancer
1998, 77(Suppl 4):8-11.
25. Van Cutsem E, Kang Y, Chung H, Shen L, Sawaki A, Lordick F, Hill J,
Lehle M, Feyereislova A, Bang Y: Efficacy results from the ToGA trial: A
phase III study of trastuzumab added to standard chemotherapy (CT) in
Lim et al. BMC Cancer 2010, 10:583
http://www.biomedcentral.com/1471-2407/10/583
Page 6 of 7first-line human epidermal growth factor receptor 2 (HER2)-positive
advanced gastric cancer (GC). J Clin Oncol 2009, 27(18s), abstr LBA4509.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2407/10/583/prepub
doi:10.1186/1471-2407-10-583
Cite this article as: Lim et al.: Retrospective analyses of cisplatin-based
doublet combination chemotherapy in patients with advanced gastric
cancer. BMC Cancer 2010 10:583.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Lim et al. BMC Cancer 2010, 10:583
http://www.biomedcentral.com/1471-2407/10/583
Page 7 of 7